Scientists identify possible therapy target for aggressive cancer

Dec 01, 2009

UT Southwestern Medical Center researchers have found that a naturally occurring protein -- transforming growth factor beta1 (TGF-ß1) -- which normally suppresses the growth of cancer cells, causes a rebound effect after a prolonged exposure. Cancer cells go into overdrive and become even more aggressive and likely to spread, the researchers report.

The mechanism for this reversal is unknown, but UT Southwestern researchers and their colleagues in Indiana suspect that cancerous cells activate a defense mechanism in response to the lethal protein. This mechanism turns on a cascade of cancer-promoting genes.

But clinicians may be able to exploit this rebound for better treatments, said Dr. David Boothman, co-senior author of the study, available online today and appearing in the January issue of The .

"These genetic changes would start prior to metastases, so if we detect them early, we might be able to tailor treatment in anticipation of a more ," said Dr. Boothman, a professor of and pharmacology and associate director of translational research in the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern. He also holds the Robert B. and Virginia Payne Professorship in Oncology.

The study was conducted on cells from mice and in samples from women with metastatic breast cancer.

TGF-ß1 controls many cellular functions, including cell growth, cell proliferation and natural cell death. It also can act to suppress tumors and prevent cancers from spreading.

The researchers, including co-senior collaborator Dr. Lindsey Mayo from the Indiana University School of Medicine, examined a cascade of biochemical reactions in cells exposed to TGF-ß1. They suspected that prolonged exposure would turn on a particular cancer-causing gene, which in turn, activates other cancer-supporting reactions.

In tissue from women with metastatic breast cancer, 60 percent of the patients showed both TGF-ß1 action and high levels of the cancer-causing gene.

The team also looked at nutlin3, a protein that blocks the action of the cancer-causing gene. They found that nutlin3 blocks the cancer-boosting effects of long-term TGF-ß1 exposure, preventing metastasis and killing . Further research will be needed to determine whether nutlin3 might be worth developing further as an anti-cancer drug, Dr. Boothman said.

Source: UT Southwestern Medical Center (news : web)

Explore further: Survival differences seen for advanced-stage laryngeal cancer

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Survival differences seen for advanced-stage laryngeal cancer

Nov 27, 2014

The five-year survival rate for advanced-stage laryngeal cancer was higher than national levels in a small study at a single academic center performing a high rate of surgical therapy, including a total laryngectomy (removal ...

Gene test aids cancer profile

Nov 27, 2014

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.